Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

Covid-19 treatment

Over the last 12 months, Revive Therapeutics (RVV.C) stock slipped 88% from $0.26 per share to a measly $0.03, but is Revive down for the count? Some analysts believe…
Edesa Biotech (EDSA.Q) announced positive results today from its Phase 2 portion of an ongoing Phase 2/3 clinical study. This study is intended to evaluate EB05, the Company’s monoclonal…
Revive Therapeutics (RVV.C) entered into a memorandum of understanding with Indian pharmaceutical company, Supriya Lifescience, which includes manufacturing, clinical registration and commercialization for Bucillamine, according to a press release….